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Abstract: The aim of this paper was to check the possible interaction of two of the four purinergic P1
receptors, the A2A and the A3. Discovery of the A2A–A3 receptor complex was achieved by means of
immunocytochemistry and of bioluminescence resonance energy transfer. The functional properties
and heteromer print identification were addressed by combining binding and signaling assays. The
physiological role of the novel heteromer is to provide a differential signaling depending on the
pre-coupling to signal transduction components and/or on the concentration of the endogenous
agonist. The main feature was that the heteromeric context led to a marked decrease of the signaling
originating at A3 receptors. Interestingly from a therapeutic point of view, A2A receptor antagonists
overrode the blockade, thus allowing A3 receptor-mediated signaling. The A2A–A3 receptor heteromer
print was detected in primary cortical neurons. These and previous results suggest that all four
adenosine receptors may interact with each other. Therefore, each adenosine receptor could form
heteromers with distinct properties, expanding the signaling outputs derived from the binding of
adenosine to its cognate receptors.
Keywords: cross-antagonism; cortical neurons; heteromer print; purinergic P1 receptors;
G-protein-coupled receptors
1. Introduction
The laboratories of Susan George and Lakshmi Devi were the first to demonstrate that two
G-protein-coupled receptors (GPCRs), for the same neurotransmitter, may form functional heterodimers.
In fact, receptor heteromers composed of different opioid receptor types were reported circa 20 years
ago [1–4]. Similarly, dopamine D1–D2 receptor heteromers were described with a particular feature,
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namely coupling to Gq. Whereas D1 couples to Gs and D2 couples to Gi, the D1–D2 heterodimer couples
to Gq, that is, neurotransmission mediated by this specific heteromer does not course with changes of
intracellular cAMP levels, but of cytoplasmic Ca2+ concentrations [5–8]. Therefore, receptor heteromers
are considered novel functional units acting differently than individually expressed receptors [9–11].
In the adenosine receptor field, the first reported heteromer resulted from a positive result in a
supposedly negative control [12]. There are four types of adenosine receptors, all belonging to the
GPCRs family. The A1 receptor (A1R) and A3 receptor (A3R) couple to Gi, whereas the A2A receptor
(A2AR) and the A2B receptor (A2BR) couple to Gs. Moreover, A1R and A2AR show high affinity for
adenosine, and the A2BR has the lowest affinity for the nucleoside. Although it was known that
adenosine may regulate calcium ion concentration in the cytoplasm of, among others, lymphocytes,
myocytes, and chondrogenic progenitor cells [13–15], to our knowledge, no report had identified Gq
proteins as coupled to adenosine receptors. Therefore, it was not expected that the A1R could interact
with the A2AR and couple to Gq as in the D1–D2 receptor heteromer. Unexpectedly, they interact and
the physiological role is quite relevant in different cell types, neurons and astrocytes included. The
heteromer is composed of two molecules of the A1R, two molecules of the A2AR, one Gs protein, and one
Gi protein. Thus, the functional unit, whose 3D structure has been proposed for the first time for a GPCR
heteromer complex, acts via A1R–Gi at low adenosine concentrations and via A2AR–Gs when adenosine
level increases. The long C-terminal domain of the A2AR intermingles within the A1R and blocks
Gi engagement upon receptor activation [16,17]. As a consequence, A1R–A2AR heteromer regulates
neurotransmitter release in glutamatergic terminals and the uptake of gamma-amino butyric acid in
astrocytes; this regulation is totally opposite at low versus at high adenosine concentrations [12,18].
Overall, the heteromer is an adenosine concentration sensing device whose dual role could not be
achieved by the individual operation of the two receptors.
Another example of interaction among adenosine receptor types is the A2AR–A2BR heteromer. On
the one hand, the expression of the A2BR, that is, the amount of heteromers, regulates A2AR-mediated
signaling. The higher the number of heteromers, the lesser the A2AR-mediated signaling, even keeping
constant the quantity of A2AR on the cell surface [19,20]. Notice that this property of the heteromer is
counterintuitive as both protomers in the heteromer are coupled to Gs and, therefore, their activation
was supposed to result in potentiation of Gs engagement. Also interesting is the recently reported role
of the A2AR–A2BR heteromer in the control of energy expenditure in adipose tissue (see details in [21]).
In recent years, the existence of the heteromer formed by the A1R and the A3R was suggested
on the basis of allosteric modulations [22]. Apart from confirming the direct interaction of these two
receptors, this observation underscores that few adenosine receptor–receptor heteromers remain to be
discovered. The aim of this study was to test the potential interaction of the Gi-coupled A3R and the
Gs-coupled A2AR. The heteromer was identified in a heterologous expression system and in primary
cultures of mouse neurons. Finally, properties of the complex in terms of signaling were assessed.
2. Results
2.1. Molecular Interaction between A2AR and A3R
Adenosine receptors are divided into high affinity A1R and A2AR types, and low affinity A2BR
and A3R types [23,24]. Members of this family interact to form heteromeric complexes, however, this
possibility has not yet explored for the A2AR and A3R types. To first address a possible interaction
between these two receptors, we performed immunocytochemical assays to look for colocalization.
We used a heterologous system consisting of human embryonic kidney HEK-293T cells, which were
transfected with A3R fused to yellow fluorescent protein (YFP), A2AR fused to Rluc, or both. The results
in Figure 1A show a marked colocalization of the signal of the two receptors; the label was mainly in the
cell surface (notice that the planes of the confocal images are taken near the surface of the slide) and did
not substantially change by previous treatment with agonists. Because of the fact that this technique
cannot demonstrate a direct interaction, we transfected HEK-293T cells with a constant amount of
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the cDNA for A2AR–Rluc and increasing quantities of the cDNA for A3R–YFP, then bioluminescence
resonance energy transfer (BRET) was determined. Interestingly, a saturation BRET curve indicating
a specific interaction between A2AR and A3R was obtained, as shown in Figure 1B. The calculated
parameters were BRETmax = 51 ± 4 mBU and BRET50 = 12 ± 3. As negative control, the same assay
was developed with a constant amount of A2AR–Rluc and increasing quantities of D4R–YFP, obtaining
a nonspecific linear signal that indicates a lack of interaction between these receptors (Figure 1B).
In summary, co-expression of the two receptors in a heterologous system leads to A2AR–A3R heteromer
(A2AR/A3R-Het) formation. Taking into account previous knowledge, receptor heteromers are formed
in the endoplasmic reticulum and traffic to the cell surface, where they complex with heteromeric G
proteins to acquire further stabilization. Indeed, the final structure is significantly modified by agonist
binding [16,17,19,21].
Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW 3 of 14 
 
that this technique cannot demonstrate a direct interaction, we transfected HEK-293T cells with a 
constant amount of the cDNA for A2AR–Rluc and increasing quantities of the cDNA for A3R–YFP, 
then bioluminescence resonance energy transfer (BRET) was determined. Interestingly, a saturation 
BRET curve indicating a specific interaction between A2AR and A3R was obtained, as shown in Figure 
1B. The calculated parameters were BRETmax = 51 ± 4 mBU and BRET50 = 12 ± 3. As negative control, 
the same assay was developed with a constant amount of A2AR–Rluc and increasing quantities of 
D4R–YFP, obtaining a nonspecific linear signal that indicates a lack of interaction between these 
receptors (Figure 1B). In summary, co-expression of the two receptors in a heterologous system leads 
to A2AR–A3R heteromer (A2AR/A3R-Het) formation. Taking into account previous knowledge, 
receptor heteromers are formed in the endoplasmic reticulum and traffic to the cell surface, where 
they complex with heteromeric G proteins to acquire further stabilization. Indeed, the final structure 
is significantly modified by agonist binding [16,17,19,21]. 
 
Figure 1. (A) Immunocytochemical assays were performed in HEK-293T cells expressing A2AR–Rluc 
(0.5 µg cDNA), which was detected by a mouse anti-Rluc antibody and a secondary anti-mouse Cy3 
conjugated antibody (red), and/or A3R–YFP (0.5 µg cDNA), which was detected by its own 
fluorescence (green). Colocalization is shown in yellow. Cells were previously treated with 100 nM 
CGS 21680, 100 nM IB-MECA, or vehicle. Cell nuclei were stained with Hoechst (blue). Scale bar: 20 
µm. (B) A2AR and A3R interact in transfected HEK-293T cells. BRET assays were performed in HEK-
293T cells transfected with a constant amount of cDNA for A2AR–Rluc (0.1 µg) and increasing 
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are the mean ± S.E.M. (n = 6 in triplicates). mBU: milliBRET units. 
2.2. Effect of the A3R Expression on Homogeneous Ligand Binding to the A2AR 
A2AR and A3R are GPCRs that, upon activation by the endogenous agonist, adenosine, initiate 
diverse signaling pathways. Thus, the analysis of ligand binding to receptors in a heteromeric context 
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2.2. Effect of the A3R Expression on Homogeneous Ligand Binding to the A2AR
A2AR and A3R are GPCRs that, upon activation by the endogenous agonist, adenosine, initiate
diverse signaling pathways. Thus, the analysis of ligand binding to receptors in a heteromeric context
becomes greatly relevant. Accordingly, competition experiments were performed using a homogenous
assay as described in Methods. HEK-293T cells expressing HALO–A2AR labeled with Lumi4-Tb were
incubated with 20 nM of a fluorophore-conjugated selective A2AR antagonist (red SCH 442416) and
increasing concentrations (0–10 µM) of the A2AR agonist, CGS 21680. As observed in Figure 2A, CGS
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21680 competed the binding of red SCH 442416 in a monophasic fashion and with a Ki value in the
nanomolar range (35 ± 1 nM), which matches with values obtained using radiolabeled ligands. At
present, there is no selective fluorophore-conjugated agonist to perform homogenous assays of binding
to HALO–A3R expressing cells. Therefore, we measured the competition of the binding of red SCH
442416 to cells co-expressing HALO–A2AR and A3R (Figure 2B). The Ki value for CGS 21680, used as
competitor, was one order of magnitude higher (427 ± 4 nM), thus suggesting that, when A2AR forms
complexes with A3R, the structure of the orthosteric site of the A2AR is modified; it cannot be ruled out
that this apparent increase in affinity is in part owing to CGS 21680 binding to the A3R.
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Figure 2. Competition experiments of SCH 442416 red ligand binding to living HEK-293T cells
expressing A2AR or A2AR/A3R-Hets. HEK-293T cells were transfected with 1µg cDNA for HALO–A2AR
in the presence (B) or in the absence (A) of 0.5 µg cDNA for A3R. Competition binding curves were
obtained by Homogeneous Time Resolved Fluorescence (HTRF) using 20 nM red SCH 442416 with
increasing concentrations of CGS 21680 (A2AR agonist) (0–10 µM). Data are the mean ± S.E.M. of a
representative experiment performed in triplicates. HTRF ratio = 665 nm acceptor signal/620 nm donor
signal × 10,000.
2.3. Functional Characterization of A2AR/A3R-Hets in HEK-293T Cells
After detecting the existence of A2AR/A3R-Hets in co-transfected HEK-293T cells, we questioned
the functional implication of this newly discovered protein–protein interaction. Thanks to A2AR
coupling to Gs protein, agonists such as CGS 21680 lead to ade ylate cyclase activation and to
increased cytosolic cAMP levels. In contrast, A3R couples to Gi and its activation leads to decreased
cytosolic cAMP concentrations. Taking into account these facts, confirmed in cells transfected with the
plasm d for one of the wo receptors, we measured cAMP levels in HEK-293T cells transfected with
cDNAs for A2AR (0.3 µg) and for A3R (0.4 µg), and treated with selective agonists. While CGS 21680
stimulation induced a marked rise in cAMP concentration, IB-MECA had no significant effect over
forskolin-induced increase in cAMP levels (Figure 3A). This result indicates that A3R–Gi coupling is
blocked in the heteromeric context, which can be considered a print to detect A2AR/A3R-Hets in native
tissues/cells. When cells were simultaneously treated with the two agonists, the effect was similar to
that obtained upon A2AR activation, thus reinforcing the hypothesis that A2AR stimulation blocks A3R
induced signaling. In the case of cells pretreated with the selective antagonists (SCH 442416 for the
A2AR or PSB-10 for the A3R), we found that SCH 442416 blocked CGS 21680-induced effects, while it
potentiated the Gi-mediated effect elicited by IB-MECA. These results suggest that antagonist binding
to A2AR leads to a structural reorganization in the A2AR/A3R-Hets that blunts the A2AR-mediated
blockade of A3R–Gi coupling (Figure 3A). For its part, the A3R antagonist (PSB-10) had no effect on
A2AR activation; no cross-antagonism of A3R over A2AR was detected.
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Next, β-arrestin 2 recruitment was analyzed in cells expressing A2AR/A3R-Hets and the findings
were similar to those obtained in cA P determination assays obtained in the absence of forskolin
(Figure 3C). In contrast, the results of ERK1/2 phosphorylation showed significant responses produced
by either the A2AR or the A3R agonist (Figure 3B). Interestingly, when the receptors were simultaneously
exposed to the two agonists, ERK1/2 phosphorylation was milder than in individual receptor
engagement. This phenomenon ay be considered as negative crosstalk. On the one hand, when
cells were pretreated with the selective antagonist for the A2AR (SCH 442416), a complete blockade
of CGS 21680-induced MAPK activation was observed, while the antagonist was ineffective on A3R
activation. On the other hand, pretreatment with the A3R antagonist (PSB-10) induced a partial
cross-antagonism on A2AR-induced ERK1/2 phosphorylation. Dynamic mass redistribution (DMR) is
a label-free technique widely used in drug discovery, especially in the field of GPCRs, that serves to
analyze cell responses in the absence of any exogenous reagent (apart from receptor ligands). The
DMR equipment detects changes upon time of the wavelength of light reflected by cells; picometer
shifts in the wavelength of photons occur when a GPCR is activated on the cell surface [25]. DMR
responses showed that the signal due to A3R activation was blocked when the A2AR was co-expressed.
Furthermore, a cross-antagonism was detected, that is, the A2AR-induced signal was blocked by
pretreatment with either A2AR or A3R antagonists (Figure 3D).
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2.4. Discovery of A2AR/A3R-Hets in Primary Cultures of Cortical Neurons
We moved to a more physiological environment to check whether the A2AR/A3R-Hets may
be expressed in a natural source. It is known that the two adenosine receptors are expressed in
different areas of the central nervous system. Owing to the implication of the adenosine receptor in
neuromodulation, we addressed the possible expression of A2AR/A3R-Hets in cortical neurons by
detecting the heteromer print.
Primary cultures of cortical neurons were prepared and cAMP determination and ERK1/2
phosphorylation assays were performed. The results in Figure 4A show that the selective A3R
antagonist (PSB-10) did not counteract the effect of the selective A2AR agonist (CGS 21680); it is one of
the features detected in HEK-293T cells. The release of the brake on A3R-mediated signaling by selective
A2AR antagonists (Figure 4B) and the cross antagonism in the link to the MAPK signaling pathway
(Figure 4C) were also detected. In summary, these data constitute strong evidence of A2AR/A3R-Hets
expression in primary cultures of cortical neurons.
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Figure 4. cAMP determination and ERK1/2 phosphorylation a says in primary cultures of cortical
neurons. l ( ,B): neurons cultured for 14 days were stimulated with selective receptor antagonists
(1 µM SCH 442416 for A2AR or 1 µM PSB-10 for A3R) and subseque tly with selective agonists (100
nM CGS 21680 for A2AR and 100 nM IB-MECA for A3R), then intracellular cAMP concentration was
det rmined. In panel B, experiments were performed in cells finally treated with 500 nM forskolin.
Values are the mean ± S.E.M. (n = 6 in triplicates). Pane (C): neurons cultured for 14 days were
stimulat d with selective antagonists for 10 min and subsequently with selective agonists for 7 min,
then ERK1/2 phosphorylation was determine . Values are the mean ± S.E.M. (n = 6 in triplicates).
One-way ANOVA followed by Bonferroni’s multiple comparison p st hoc test were used for significance
analysis. * p < 0.05, ** p < 0.01, and **** p < 0.0001 versus vehicle treatment (basal); # p < 0.05, ### p < 0.001
versus agonist treatment. &&&& p < 0.0001 versus forskolin treatment.
3. Discussion
This paper discovers a new complex formed by two different adenosine receptors that may be
expressed in a heterologous system, but also in primary cultures of cortical neurons. The heteromer
print is quite unique as antagonists of the A2AR enhance A3R-mediated signaling.
Especially unexpected was the discovery of heteromers formed by two receptors of the same
neurotransmitter/hormone that are in complex with different cognate (heterotrimeric) G proteins. One
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possibility is a shift in the G-protein-coupling. In fact, the dopamine D1–D2 heteroreceptor does not
couple to Gs nor to Gi, but to Gq [5–8]. However, in the case of the A1R–A2AR heteromer, there is
no shift in G-protein coupling, but the overall structure allows increasing or decreasing cAMP levels
depending on the concentration of the endogenous agonist. Adenosine preferentially activates the A1R,
thus engaging Gi proteins. Nevertheless, when adenosine level increases and the A2AR is activated
within the heteromer, Gi-coupling is blunted and Gs engagement occurs. The molecular determinants
that make this possible are detailed elsewhere [16,17], but it is worth mentioning that the C-terminal
domain of the A2AR plays a fundamental role.
The A2BR is the most enigmatic adenosine receptor; it has a very reduced affinity for the nucleoside
and it is also the receptor for netrin, which belongs to a family of proteins involved in axon guidance [26].
On the one hand, comparison of the structural arrangement of A2AR and A2BR has led to the discovery
that the second extracellular loop determines low (A2BR) or high (A2AR) affinity for adenosine [27]. On
the other hand, as earlier commented, the expression of the A2BR reduces the A2AR-mediated functions
by means of the formation of A2A–A2B heteroreceptor complexes. Thus, it seems that the A2BR, per
se or negatively acting on the A2AR, contributes to reducing the actions derived from extracellular
adenosine accumulation.
The properties of the heteromer described here are different from those previously defined for
adenosine receptor heterocomplexes. A simple scheme summarizing the operation of A2AR/A3R-Hets
is provided in Figure 5. One of the features of A2AR/A3R-Hets is common to several heteromers,
namely cross-antagonism [9,28,29]. However, the most important characteristic is that the A3R
functionality is negligible within the A2AR/A3R-Het. Importantly, selective A2AR antagonists release
the brake on A3R activation. This finding adds a new piece in the puzzle of both purinergic and
GPCR-heteromer-mediated signaling. This specific feature may be of interest in drug discovery in a
time when adenosine receptors are gaining momentum after the approval (in Japan and the USA) of
istradefylline, a selective A2AR antagonist, as adjuvant therapy in Parkinson’s disease [30–34].
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4. Materials and Methods
4.1. Reagents
CGS 21680 hydrochloride, IB-MECA, SCH 442416 and PSB-10 hydrochloride were purchased from
Tocris Bioscience (Bristol, UK). Forskolin was purchased from Sigma-Aldrich (St. Louis, MO, USA). For
non-radioactive binding assays, tag-lite buffer (TLB) was obtained from Cisbio Bioassays (LABMED,
Codolet, France). The Tb derivative of O6-benzylguanine is commercialized as HaloTag-Lumi4-Tb
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(SHALOTBC, Cisbio Bioassays, LABMED, Codolet, France). A2AR antagonist (SCH 442416 derivate)
conjugated to a red fluorescent probe was purchased from Cisbio Bioassays (L0058RED, LABMED,
Codolet, France). The intellectual property of TLB components and of fluorophore structure is owned
by Cysbio Bioassays.
4.2. Neuronal Primary Cultures
By the current legislation, obtaining protocol approval is not needed if animals are sacrificed to
obtain a specific tissue. CD-1 strain mice handling, sacrifice, and further experiments were conducted
according to the guidelines set in Directive 2010/63/EU of the European Parliament and the Council
of the European Union that is enforced in Spain by National and Regional organisms; the 3R rule
(replace, refine, reduce) for animal experimentation was also taken into account. Primary cultures
of cortical neurons were obtained from 19-day embryos. Cells were isolated as described in [35]
and plated at a confluence of 40,000 cells/0.32 cm2. Cells were maintained for 14 days in Neurobasal
medium supplemented with 2 mM L-glutamine, 100 U/mL penicillin/streptomycin, and 2% (v/v) B27
supplement (Gibco, Paisley, Scotland, UK), in six-well plates for functional assays.
4.3. Cell Culture and Transient Transfection
HEK-293T cells were grown in DMEM medium (Gibco, Paisley, Scotland, UK) supplemented
with 2 mM L-glutamine, 100 U/mL penicillin/streptomycin, MEM non-essential amino acids solution
(1/100), and 5% (v/v) heat inactivated fetal bovine serum (FBS) (Invitrogen, Paisley, Scotland, UK). Cells
were maintained in a humid atmosphere of 5% CO2 at 37 ◦C, and were transiently transfected with
plasmids for fusion proteins containing sequences encoding for human A2AR (Gene ID: 135; GenBank:
X68486.1) and/or human A3R (Gene ID: 140; GenBank: B029831.1) using the PEI (polyethylenimine,
Sigma-Aldrich, St. Louis, MO, USA) method, as previously described [17,36]. Cells were used 48 h
later for functional assays.
4.4. Fusion Proteins and Expression Vectors
The human cDNAs for the A2AR and A3R cloned in pcDNA3.1 were amplified without their stop
codons using sense and antisense primers harboring either unique BamHI and XhoI sites for A3R and
Hind III and BamHI sites for A2AR. The fragments were subcloned to be in frame with the sequence
coding for an enhanced YFP (pEYFP-N1; Clontech, Heidelberg, Germany) or a Rluc protein (pRluc-N1,
PerkinElmer, Wellesley, MA, USA). Final cDNAs encoding for A2AR–YFP, A2AR–Rluc and A3R–YFP,
and fusion proteins having the receptor at the N-terminal end.
After transfection with the corresponding plasmids, the health and viability of transfected cells
were proved using the appropriate negative controls. In addition, expression of receptors was tested
by either fluorescent confocal microscopy (Figure 1A) or Rluc expression, and receptor function was
tested by performing ERK1/2 activation assays. Using Trypan Blue solution (T8154, Sigma-Aldrich,
St. Louis, MO, USA), the percentage of non-viable cells when collected for experiment performance
was <15.
4.5. Bioluminescence Resonance Energy Transfer (BRET) Assays
HEK-293T cells growing in six-well plates were transiently co-transfected with a constant amount
of cDNA encoding for A2AR–Rluc and with increasing concentrations of cDNAs for A3R–YFP or
D4R–YFP as negative control. Forty-eight hours post-transfection, cells were washed twice in Hank’s
Balanced Salt Solution (HBSS; 137 mM NaCl, 5 mM KCl, 0.34 mM Na2HPO4, 0.44 mM KH2PO4,
1.26 mM CaCl2, 0.4 mM MgSO4, 0.5 mM MgCl2, and 10 mM HEPES, pH 7.4) supplemented with 0.1%
glucose (w/v), detached by gently pipetting and resuspended in the same buffer. To assess the number
of cells per plate, protein concentration was determined using a Bradford assay kit (Bio-Rad, Munich,
Germany) with bovine serum albumin dilutions as standards. To quantify YFP-fluorescence expression,
cell suspension (20 µg protein) was distributed in 96-well microplates (black plates with a transparent
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bottom, Porvair, Leatherhead, UK). Fluorescence was read using a Mithras LB 940 (Berthold, Bad
Wildbad, Germany) equipped with a high-energy xenon flash lamp, using a 10 nm bandwidth excitation
and emission filters at 485 nm and 530 nm, respectively. YFP-fluorescence expression was determined
as the fluorescence of the sample minus the fluorescence of cells only expressing protein-Rluc. For BRET
measurements, the equivalent to 20 µg cell suspension was distributed in 96-well microplates (white
plates, Porvair, Leatherhead, UK), and 5 µM coelenterazine H was added (PJK GMBH, Kleinblittersdorf,
Germany). One minute after coelenterazine H addition, the readings were collected using a Mithras
LB 940 (Berthold, Bad Wildbad, Germany), which allowed the integration of the signals detected in the
short-wavelength filter at 485 nm (440–500 nm) and the long-wavelength filter at 530 nm (510–590 nm).
To quantify receptor-Rluc expression, luminescence readings were collected 10 min after addition of
5 µM coelenterazine H. The net BRET is defined as [(long-wavelength emission)/(short-wavelength
emission)]-Cf, where Cf corresponds to [(long-wavelength emission)/(short-wavelength emission)]
for the Rluc construct expressed alone in the same experiment. Data in BRET curves that depict
an equilateral hyperbola were fitted by a non-linear regression equation using the GraphPad Prism
software (San Diego, CA, USA). BRET values for specific interactions are given as milli BRET units
(mBU: 1000 × net BRET).
4.6. Immunocytochemistry
Transfected HEK-293T cells expressing A3R–YFP and/or A2AR–Rluc were treated with vehicle, with
100 nM CGS 21680, or with 100 nM IB-MECA for 30 min. Then, cells were fixed in 4% paraformaldehyde
for 15 min and washed twice with PBS containing 20 mM glycine before permeabilization with the same
buffer containing 0.2% Triton X-100 (5 min incubation). Cells were treated for 1 h with PBS containing 1%
bovine serum albumin, labeled with a mouse anti-Rluc (1/100, MAB4400, Millipore, Merck, Darmstadt,
Germany) antibody, and subsequently treated with a Cy3-conjugated anti-mouse (1/200, 715-166-150
(red), Jackson ImmunoResearch, St. Thomas Place, UK) IgG secondary antibody (1 h each). Samples
were washed several times and mounted with 30% Mowiol (Calbiochem, Merck, Darmstadt, Germany).
Samples were observed under a Leica SP2 confocal microscope (Leica Microsystems, Wetzlar, Germany).
4.7. Homogeneous Competition Binding Assays in Living Cells
HEK-293T cells expressing HALO-tagged A2AR in the presence or in the absence of A3R were
seeded in six-well plates. After 48 h, medium was removed and cells were treated with 100 nM
HALOTag-Lumi4-Tb, previously diluted in 3 mL TLB 1X, for 1 h at 37 ◦C under 5% CO2 atmosphere
in a cell incubator. Cells were then washed four times with 2 mL TLB 1X to remove the excess of
HALOTag-Lumi4-Tb, detached with enzyme-free cell dissociation buffer, centrifuged 5 min at 1500 rpm,
and collected in 1 mL TLB 1X. Cells at densities in the 2500–3000 cells/well range were plated in white
opaque 384-well plates (10 µL). Then, 5 µL of 20 nM fluorophore-conjugated A2AR antagonist were
added in the presence of vehicle or of CGS 21680 hydrochloride at increasing concentrations (0–10 µM
range, 5 µL total volume). Plates were then placed at room temperature for 2 h before signal detection.
Detailed description of the HTRF assay is found in [37]. Signal was detected using an PheraSTAR
microplate reader (PerkinElmer, Waltham, MA, USA) equipped with a Fluorescence Resonance Energy
Transfer (FRET) optic module allowing donor excitation at 337 nm and signal collection at both 665
and 620 nm. A frequency of 10 flashes/well was selected for the xenon flash lamp excitation. The
signal was collected at both 665 and 620 nm using the following time-resolved settings: delay: 150 µs
and integration time: 500 µs. HTRF ratios were obtained by dividing the acceptor (665 nm) by the
donor (620 nm) signals and multiplying by 10,000. The 10,000-multiplying factor is used solely for the
purpose of easier data handling.
4.8. cAMP Determination
For cAMP studies, HEK-293T transfected cells and cortical neurons were prepared. Signaling
experiments were performed as previously described [16,17,19,38]. Briefly, 2 h before initiating the
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experiment, cell-culture medium was replaced by serum-free DMEM medium. Then, cells were
detached, resuspended in growing medium containing 50 µM zardaverine, and placed in 384-well
microplates (2500 cells/well). Cells were pretreated (15 min) with antagonists (SCH 442416 for A2AR
and/or PSB-10 for A3R) and stimulated with agonists (CGS 21680 for A2AR and/or IB-MECA for A3R)
(15 min) before adding 0.5 µM forskolin or vehicle. Readings were performed after 1 h incubation at
25 ◦C. HTRF energy transfer measures were performed using the Lance Ultra cAMP kit (PerkinElmer,
Waltham, MA, USA). Fluorescence at 665 nm was analyzed in a PHERAstar Flagship microplate reader
equipped with an HTRF optical module (BMG Lab Technologies, Offenburg, Germany).
4.9. ERK Phosphorylation Assays
To determine ERK1/2 phosphorylation, HEK-293T transfected cells and cortical neurons were
seeded at a density of 40,000 cells/well in transparent Deltalab 96-well microplates, and kept at the
cell incubator. Two hours prior to the experiment, the medium was substituted by serum-free DMEM
medium. Then, cells were pre-treated for 10 min at 25 ◦C with antagonists (SCH 442416 for A2AR
and/or PSB-10 for A3R) in serum-free DMEM medium and stimulated for an additional 7 min with
the selective agonists (CGS 21680 for A2AR and/or IB-MECA for A3R). Then, cells were washed twice
with cold PBS before the addition of lysis buffer (15 min treatment). Then, 10 µL of each supernatant
was placed in white ProxiPlate 384-well microplates and ERK1/2 phosphorylation was determined
using AlphaScreen®SureFire® kit (Perkin Elmer, Waltham, MA, USA), following the instructions of
the supplier and using an EnSpire® Multimode Plate Reader (PerkinElmer, Waltham, MA, USA).
4.10. Dynamic Mass Redistribution (DMR) Assays
Cell mass redistribution induced upon receptor activation was detected by illuminating the
underside of a biosensor with polychromatic light and measuring the changes in the wavelength of
the reflected monochromatic light. The magnitude of wavelength shifts (in picometers) is directly
proportional to the amount of DMR. Transfected HEK-293T cells were seeded in 384-well sensor
microplates to obtain 70–80% confluent monolayers constituted by approximately 10,000 cells per well.
Prior to the assay, cells were washed twice with assay-buffer (HBSS with 20 mM HEPES, pH 7.15) and
incubated for 2 h with assay-buffer containing 0.1% dimethyl sulfoxide (DMSO) (24 ◦C, 30 µL/well).
Hereafter, the sensor plate was scanned and a baseline optical signature was recorded for 10 min
before adding 10 µL of antagonist solution (SCH 442416 for A2AR and/or PSB-10 for A3R) for 30 min,
followed by the addition of 10 µL of agonist solution (CGS 21680 for A2AR and/or IB-MECA for A3R).
The label-free signature was determined using an EnSpire® Multimode Plate Reader (PerkinElmer,
Waltham, MA, USA). DMR responses were monitored for at least 5000 s. The results were analyzed
using EnSpire® Workstation Software v 4.10 (PerkinElmer, Waltham, MA, USA).
4.11. β-arrestin 2 Recruitment
β-arrestin 2 recruitment was determined as previously described [17,36]. Briefly, BRET experiments
were performed in HEK-293T cells 48 h after transfection with the cDNA corresponding to A2AR–YFP or
A3R–YFP (0.5 µg cDNA each) and 1 µg cDNA corresponding to β-arrestin 2-Rluc. Cells (20 µg protein)
were distributed in 96-well microplates (Corning 3600, white plates with white bottom) and were
incubated with antagonists (SCH 442416 for A2AR and/or PSB-10 for A3R) for 15 min and stimulated
with agonists (CGS 21680 for A2AR and/or IB-MECA for A3R) for 10 min prior to the addition of 5 µM
coelenterazine H (Molecular Probes, Eugene, OR, USA). One minute after coelenterazine H addition,
BRET between β-arrestin 2-Rluc and receptor-YFP was determined and quantified. The readings were
collected using a Mithras LB 940 (Berthold Technologies, Bad Wildbad, Germany) that allows the
integration of the signals detected in the short-wavelength filter at 485 nm and the long-wavelength
filter at 530 nm. To quantify protein-Rluc expression, luminescence readings were also performed 10
min after adding 5 µM coelenterazine H.
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4.12. Data Handling and Statistical Analysis
Data from homogeneous binding assays were analyzed using Prism 6 (GraphPad Software, Inc.,
San Diego, CA, USA). Ki values were determined according to the Cheng and Prusoff equation with
KD = 20 nM for A2AR red antagonist [39]. Signal-to-background (S/B ratio) calculations were performed
by dividing the mean of the maximum value (µmax) by that of the minimum value (µmin) obtained
from the sigmoid fits.
The data are mainly shown as the mean ± S.E.M. Statistical analysis was performed with SPSS 18.0
software. The test of Kolmogorov–Smirnov with the correction of Lilliefors was used to evaluate normal
distribution and the test of Levene was used to evaluate the homogeneity of variance. Significance was
analyzed by one-way ANOVA, followed by Bonferroni’s multiple comparison post hoc test. Significant
differences were considered when p < 0.05.
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A2AR/A3R-Het A2A–A3 receptor heteromer
A2BR A2B receptor
A3R A3 receptor
BRET Bioluminescence resonance energy transfer
DMR Dynamic mass redistribution
DMSO Dimethyl sulfoxide
FBS Fetal bovine serum
FRET Fluorescence resonance energy transfer
GPCRs G-protein-coupled receptors
HBSS Hank’s balanced salt solution
HTRF Homogeneous time resolved fluorescence
TLB Tag-lite buffer
YFP Yellow fluorescent protein
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